Alteogen Showcases ALT-B4's Potential to Transform ADC Development at World ADC Summit 2026
PR Newswire
DAEJEON, South Korea, June 10, 2026
Preclinical data demonstrate enhanced systemic exposure and bioavailability, reduced dermal toxicity, and improved safety profile in ALT-B4-enabled ADC therapyKey PointsSuperior PK: Subcutaneous administration of ADCs combined with ALT-B4 demonstrated rapid absorption, enhanced systemic exposure, and improved bioavailability compared to SC administration without ALT-B4Reduced local toxicity: The ALT-B4 combination SC group showed a notable, dose-dependent reduction in local dermal toxicity at the injection siteImproved hematologic safety: Compared to IV infusion, the ALT-B4 combination SC group exhibited lower reductions in absolute neutrophil count (ANC) and mitigated elevations in triglycerides and AST, indicating a favorable safety profileDAEJEON, South Korea, June 10, 2026 /PRNewswire/ -- Alteogen Inc. (KOSDAQ: 196170), a leading biopharmaceutical company specializing in platform technologies, announced today that it presented preclinical data at the World ADC Summit South Korea on the subcutaneous (SC) formulation of antibody-drug conjugates (ADCs) using its proprietary hyaluronidase ALT-B4 (berahyaluronidase alfa).
